4sc Ag

Immunic Ag

4sc Discovery Gmbh

Mirko Zaja

Stefan Tasler

Johann Leban

Juergen Kraus

Ilga Krimmelbein

Jakob Felding

Daniel Vitt

Hella Kohlhof

Manfred Gröppel

Carine Chevrier

Manfred Groppel

Rolf Andreas Muhler

Rolf Andreas MÜHLER

The present invention relates to compounds of the general formula (I), and the pharmaceutically acceptable salts and solvates thereof, wherein Ar, Z and Y are as described herein and R1 is a group of the structure wherein n is 0 or 1; R2 is H, deuterium or methyl; R3 is methyl, trifluoromethyl, ethyl, or taken with R2 together forms a cyclopropyl group, or R3 forms a methylene bridge to the carbon atom marked *, which are suitable for the treatment of autoimmune diseases and chronic inflammation. 

IL-17 and IFN-gamma inhibition for the treatment of autoimmune diseases and chronic inflammation

Compounds of formula (II) or a pharmaceutically acceptable salt or solvate thereof, the medical uses thereof for diseases or medical conditions where the inhibition of the voltage-gated potassium channel Kv1.3 is beneficial, and methods for their preparation.

KV1.3 inhibitors and their medical application

Kv1.3 inhibitors and their medical application

The present invention relates to compounds of below Formula (I), physiologically functional derivatives or salts thereof, where the groups R, R, R, R, R, X, and A, as well as the variables n, m and p are detailed further herein. 

2,3-dihydrobenzofuran-5YL compounds as DYRK kinase inhibitors

The invention relates to a compound of the general formula (I) or a physiologically functional derivative, solvate or salt thereof, wherein

Bifluorodioxalane-amino-benzimidazole kinase inhibitors for the treatment of cancer, autoimmuneinflammation and CNS disorders

Growing community of inventors

Munich, Germany

Mirko Zaja